Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 82

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 82
---
 million deaths and contributed to 5.35 million deaths in 2022. In the US alone, antimicrobial resistance was responsible
for 47,000 deaths and contributed to 180,000 deaths in 2022. [1]. These numbers are echoed by the 2022 report published by WHO. Health
management organizations and medical professionals around the world increasingly recognize antimicrobial resistance (AMR) as one of the
most urgent and escalating threats to global health and sustainable development.

We believe that our novel liposomal Nano-Mupirocin
product candidate may potentially present significant advancement in antibiotic therapy by enabling systemic use of mupirocin, a potent
topical antibiotic previously ineffective in systemic applications due to rapid degradation in blood. Through a PEGylated liposomal delivery
system, we believe that Nano-Mupirocin can be designed to achieve intracellular delivery, prolonged circulation time, and improve biodistribution
to the affected by the resistant bacterial tissue. This technology we are working to develop fills a critical therapeutic gap, particularly
for multidrug-resistant pathogens such as MRSA, VRE, rapidly emerging resistant pathogens of Gonorrhea, and others.

We believe that Nano-Mupirocin can address the
global Anti-Microbial Resistance (AMR) crisis by enabling highly potent systemic therapy for high-risk infections with limited existing
treatment options. The platform is being designed to offer improved affected tissue-selective delivery and intracellular access, unlike
current untargeted broad-spectrum antibiotics. We believe that our product candidate is being developed to establish a new therapeutic
standard and to potentially introduce a new class of liposomal anti-infective agents.

<div align='center'>49</div>

Nano-Mupirocin technology overview

The nano-liposomal formulation
of Mupirocin is enhanced by adding hydroxypropyl-beta-cyclodextrin (HPCD) to the intraliposomal volume, allowing for Mupirocin controlled
release from the liposomes in blood. The novel Nano-Mupirocin’s efficacy has been demonstrated in various animal models, with two
of these studies sponsored by the National Institute of Health (US). Its pharmacokinetic profile in animal studies demonstrated increased
systemic exposure compared to the free drug, together with a substantially extended half-life. The in vitro spectrum of activity
for both Mupirocin and our liposomal Nano-Mupirocin was tested on many clinical isolates, showing no cross-resistance with other antibiotics.
Interestingly,